English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

To find new contrast agents for magnetic resonance imaging (MRI), the spin-lattice relaxation time (T1)-reducing activities of metal complexes of EDTA, N-hydroxyethyethylenediamine-N,N',N'-triacetic acid (HEDTA), diethylenetriamine-N,N,N',N'',N''-pentaacetic acid (DTPA), deferoxamine, mugineic acid, and pectin with Fe(III) or Mn(II) were investigated. Strong activity was found in Fe(III)-deferoxamine, Fe(III)-mugineic acid, or Mn(II)-pectin. In the actual MRI tomogram, Fe(III)-deferoxamine exhibited a contrast-enhancing effect comparable with that of Gd(III)-DTPA, and a much stronger effect was observed for Mn(II)-pectin. Fe(III)-deferoxamine and the Mn(II)-pectin appear to be candidates, respectively, as a new intravenous contrast agent and an oral gastrointestinal one.

biological and pharmaceutical bulletin

Inorganic Chemical Approaches to Pharmacognosy. XIV. Characterization of Fe(III)-Deferoxamine and Mn(II)-Pectin as Magnetic Resonance Imaging Contrast Agents.